<DOC>
	<DOCNO>NCT00901914</DOCNO>
	<brief_summary>The purpose study determine efficacy safety three dos r Bet v1 administer sublingual tablet birch pollen allergic subject .</brief_summary>
	<brief_title>Study rBet v1 Tablets</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>Symptomatic birch pollenrelated allergic rhinoconjunctivitis least last 2 pollen season Sensitisation birch pollen demonstrate , screen , positive SPT birch pollen wheal diameter great 3 mm specific IgE level &gt; 0.70 kU/L ( birch pollen rBet v 1 ) Patients asymptomatic allergen birch pollen season RRTSS previous pollen season ≥ 12 maximum possible score 18 Patients FEV1 ≥ 80 % predict value Female patient childbearing potential Female patient childbearing potential eligible sexually active use medically accept contraceptive method negative urine pregnancy test , willing able sign write informed consent state use appropriate contraception plan pregnancy study Patients able compliant respect completion daily record card take investigational product Patients provide sign informed consent Patients symptoms rhinoconjunctivitis birch pollen season due nonbirchrelated allergens Patients symptomatic allergic rhinitis/rhinoconjunctivitis due house dust mites Patients symptomatic allergic rhinitis/rhinoconjunctivitis due cat dog allergen , live animal home risk frequent contact animal ( family , friends etc . ) course study Patients previously receive desensitisation treatment birch pollen and/or another Betulaceae sp . within previous 10 year Patients asthma ( except birch seasonal asthma case patient could include study ) Patients nasal oral condition could interfere efficacy safety assessment ( nasal polyposis oral inflammation ) Patients past current disease , judge investigator , may affect patient 's participation outcome study Any disease condition would place patient undue risk include study ( accord investigator 's opinion ) Usual contraindication immunotherapy concomitant local systemic betablocker therapy and/or immunosuppressive drug Patients ongoing treatment immunotherapy another allergen Patients treat inhaled/systemic steroid within 4 week prior Screening , long act systemic corticosteroid 12 week Screening Patients continuous corticotherapy undergo chronic treatment H2antihistamine drug Known hypersensitivity mannitol Pregnancy , breastfeeding/lactation sexually active woman childbearing potential use medically accept contraceptive method Patients history drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Hypersensitivity</keyword>
	<keyword>Allergy</keyword>
	<keyword>Birch , allergy , Sublingual Immunotherapy</keyword>
</DOC>